• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>ITT Corp.

ITT Corp.

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. ITT Reports 2016 Fourth-Quarter and Full-Year Results, 2017 Guidance

    ITT Reports 2016 Fourth-Quarter and Full-Year Results, 2017 Guidance

  2. ITT to Participate in Gabelli & Company’s 27th Annual Pump, Valve and Water Systems Symposium

    ITT to Participate in Gabelli & Company’s 27th Annual Pump, Valve and Water Systems Symposium

  3. Gabelli & Company’s 27th Annual Pump, Valve & Water Systems Symposium

    Gabelli & Company’s 27th Annual Pump, Valve & Water Systems Symposium

  4. Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

    Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

  5. Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™

    Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™

  6. Harris Corporation Reports Fiscal 2017 Second Quarter Results

    Harris Corporation Reports Fiscal 2017 Second Quarter Results

  7. Our 4 Nominees for Allocation Fund Manager of the Year

    These nominees handled a wide range of assets with notable skill.

123

©2017 Morningstar Advisor. All right reserved.